WallStSmart

Jasper Therapeutics Inc (JSPR)vsModerna Inc (MRNA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

JSPR leads profitability with a 0.0% profit margin vs -141.4%. MRNA earns a higher WallStSmart Score of 21/100 (F).

JSPR

Avoid

19

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 4.5
Piotroski: 1/9Altman Z: -18.58

MRNA

Avoid

21

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 6.7Quality: 7.5
Piotroski: 3/9Altman Z: 2.09
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for JSPR.

MRNAUndervalued (+70.0%)

Margin of Safety

+70.0%

Fair Value

$134.97

Current Price

$143.97

$9.00 discount

UndervaluedFair: $134.97Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JSPR1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

MRNA2 strengths · Avg: 9.0/10
Market CapQuality
$56.02B9/10

Large-cap with strong market position

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

Areas to Watch

JSPR4 concerns · Avg: 3.8/10
Price/BookValuation
13.2x4/10

Trading at 13.2x book value

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$23.46M3/10

Smaller company, higher risk/reward

MRNA4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Revenue GrowthGrowth
2.1%4/10

2.1% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-46.6%2/10

ROE of -46.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : JSPR

The strongest argument for JSPR centers on Debt/Equity.

Bull Case : MRNA

The strongest argument for MRNA centers on Market Cap, Debt/Equity.

Bear Case : JSPR

The primary concerns for JSPR are Price/Book, Revenue Growth, EPS Growth.

Bear Case : MRNA

The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

JSPR profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.

JSPR carries more volatility with a beta of 3.03 — expect wider price swings.

MRNA is growing revenue faster at 2.1% — sustainability is the question.

JSPR generates stronger free cash flow (-7M), providing more financial flexibility.

Bottom Line

MRNA scores higher overall (21/100 vs 19/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Jasper Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Jasper Therapeutics Inc (JSPR) is a pioneering biopharmaceutical company dedicated to advancing hematopoietic stem cell therapies aimed at improving treatment outcomes for patients suffering from severe conditions such as sickle cell disease and specific hematologic malignancies. Leveraging state-of-the-art technologies, Jasper seeks to minimize transplant-related complications, addressing critical unmet needs in the hematology and oncology fields. Supported by a robust intellectual property portfolio and strategic collaborations, the company is well-positioned to drive innovation and propel its clinical pipeline forward, underscoring its commitment to transformative solutions in regenerative medicine.

Moderna Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.

Want to dig deeper into these stocks?